Send to

Choose Destination
Neural Regen Res. 2019 Mar;14(3):437-440. doi: 10.4103/1673-5374.245463.

Multitarget therapeutic strategies for Alzheimer's disease.

Author information

Department of Pharmacognosy, Faculty of Pharmacy, Mansoura University, Mansoura, Egypt; Department of Basic Pharmaceutical and Toxicological Sciences, College of Pharmacy, University of Louisiana at Monroe, Monroe, LA, USA.
Department of Medicinal Chemistry, Faculty of Pharmacy, Mansoura University, Mansoura, Egypt; Department of Chemistry, University of Iowa, Iowa City, IA, USA.


Neurodegenerative diseases such as Alzheimer's, Huntington's and Parkinson's diseases have multifaceted nature because of the different factors contributing to their progression. The complex nature of neurodegenerative diseases has developed a pressing need to design multitarget-directed ligands to address the complementary pathways involved in these diseases. The major enzyme targets for development of therapeutics for Alzheimer's disease are cholinesterase and β-secretase enzymes. In this review, we discuss recent advances in profiling single target inhibitors based on these enzymes to multitarget-directed ligands as potential therapeutics for this devastating disease. In addition, therapeutics based on iron chelation strategy are discussed as well.


Alzheimer's disease; acetylcholinesterase; brain permeability; hybridization; multitarget-directed ligands; neurodegenerative diseases; tacrine; β-secretase

Free full text

Supplemental Content

Full text links

Icon for Medknow Publications and Media Pvt Ltd
Loading ...
Support Center